Compare KTOS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTOS | RDY |
|---|---|---|
| Founded | 1994 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.9B |
| IPO Year | 1999 | 2001 |
| Metric | KTOS | RDY |
|---|---|---|
| Price | $57.17 | $12.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $96.71 | $16.90 |
| AVG Volume (30 Days) | ★ 3.8M | 2.9M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $751,900,000.00 | N/A |
| Revenue This Year | $26.15 | $7.72 |
| Revenue Next Year | $23.43 | $3.50 |
| P/E Ratio | $623.40 | ★ $18.67 |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $43.09 | $11.36 |
| 52 Week High | $134.00 | $15.67 |
| Indicator | KTOS | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 44.06 |
| Support Level | $52.49 | $11.47 |
| Resistance Level | $58.88 | $12.58 |
| Average True Range (ATR) | 3.78 | 0.20 |
| MACD | -0.16 | 0.06 |
| Stochastic Oscillator | 43.56 | 59.50 |
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.